Diabeties The Cure!? Could be, need your help!!
Hello there! and thank you for your support, I am no longer as closely involved with Dr. Faustmans lab as I could be sadly. But If you wish to keep up with her and her team or wish to donate to her directly please the Faustmanlab.org
What is today on here page…..
“Support the Faustman Lab
The research conducted by the Faustman Lab receives no Federal funding and is 100% supported by philanthropic individuals and foundations.
Your gift of any amount will support the Faustman Lab’s search for a type 1 diabetes cure. Make gift today.
How to Help
There are many ways that you can support the work of the Faustman Lab. Making an outright gift online using a credit card is the most convenient. If your prefer to make a donation via check, you can do so by making your check out to “Massachusetts General Hospital – Faustman Research” and mailing it to:
MGH Development Office
Attn: Jocelyn Hoey
165 Cambridge Street, Suite 600
Boston, MA 02114
You can also run a fundraiser or other event to benefit the Faustman Lab or help spread the word about our work.
Cure Diabetes Now Fund
To support the Faustman Lab’s work, the Cure Diabetes Now Fund was established. The Cure Diabetes Now Fund is operated by Massachusetts General Hospital, an institution with 501c3, non-profit status. Your gift to the fund is tax-deductible to the extent provided by law.
Support the Clinical Trials
The Faustman Lab is now conducting human clinical trials with BCG, a widely-used, inexpensive generic drug that may help to remove the “bad” cells that cause type 1 diabetes. These clinical trials are unique because they are focused on people living with diabetes, as opposed to only those who have been newly-diagnosed. Most importantly, the goal of Dr. Faustman’s clinical trials is to develop a cure for diabetes, not just manage the condition.
Phase I of the clinical trials began in January 2008 and is fully funded. With your support, Phase II will begin in late 2009. Phase II will last three years and will cost approximately $25 million. At least $8.4 million will be needed by late 2009 to initiate the first year of Phase II.”
Now Back to the old post that was always here with some more info……….
Here is the latest post about her determination to cure diabetes……The Cure is Here!
Help me by sponsoring me to do the trials at MGH Hospital in Boston Mass. Leave me a comment below this post.
DiabetesWebSearch.com (http://www.diabeteswebsearch.com) is answering tough diabetes questions while funding the only clinical trial to cure type 1 diabetes.
The trial, conducted by Dr. Denise Faustman’s Lab at the Massachusetts General Hospital, is a follow-up to the landmark study that permanently cured diabetic mice for the first time. They are testing their technique in humans with type 1 diabetes. (Watch Dr. Faustman explain how the diabetes cure works (http://www.diabetesdaily.com/edelman/2008/09/diabetes-cure.php).)
Dr. Faustman points to DiabetesWebSearch.com as helpful addition to her work: “My colleagues and I appreciate the support DiabetesWebSearch.com will provide for the clinical trial.”
DiabetesWebSearch.com is the result of a partnership between Bernard Farrell (http://bernardfarrell.com/), DiabetesDaily.com (http://www.diabetesdaily.com) and TuDiabetes.com (http://www.tudiabetes.com). The project started in mid-2007, when Bernard Farrell launched the Diabetes Search Engine. Farrell is software developer and a leading voice in the diabetes community through his Diabetes Technology Blog.
Farrell was moved to support Dr. Faustman’s research after learning that it was completely self-funded. Because the potential cure uses approved, patent-free drugs, the lab cannot get funding from pharmaceutical companies. Although phase 1 of the clinical trial is fully funded, Dr. Faustman will need $25 million to complete phase 2.
Read More HERE………..
Merrill Goozner, director of the Integrity in Science Project for The Center for Science in the Public Interest was disturbed to see the JDRF go to such great lengths to discredit Faustman. “It is shocking to see that scientists, rather than evaluating something on its merits, would spend so much time attacking the messenger,” he said. “You have to wonder, what is their real motivation? You would think that scientists connected with the JDRF would be pursuing every effective cure, not attacking approaches that rival their own.”
End Quote! Click here to read more…….
There is still a growing need for blood, the more people that come to Boston to donate blood will help everyone in the long run. Diabetic blood donations for the research, We need you to come with controls!! Controls are people that come with you to donate their blood to help with the study. Please TYPE 1 Diabetics Needed Contact Heather at faustman Labs Now!!
Her current research continues to focus on uncovering new treatments for type 1 diabetes, as well as searching for therapies for other autoimmune diseases, including Crohn’s disease, lupus, scleroderma, rheumatoid arthritis, Sjogren’s syndrome, and multiple sclerosis.
I F you are willing perhaps we could go as a large group, charter a bus from Kitchener to Buffalo to take a plane, or we might even charter a plane to logan or near by landing field. If your into helping with the study for the cure leave a comment below. NO MORE FOUND DEAD IN BED SYNDROME!!
Spring News letter of Faustman spring 2008 newsltr
See this page for what research that has been found http://www.iacoccafoundation.org/grants_diabetes_research.html
Sooner than expected, some have already found the posting of Phase one trials with Denise Faustman. Phase one is more for the FDA, they seem to be treating this findings as a new drug! They are being overly cautious. BCG has been administered to people who were diagnosed with Malaria for over twenty years so this Phase one seems almost useless, but according to FDA standarts it must be done for new drugs. Humm wonder why it needs to be done in this case?? Any ideas anyone?
ALSO please, i understand why your hopes are not too high, but lets see here, lets call this the most promising cure of all time. The BCG may not be the ultimate answer but the development of the known findings will help to know and overcome the illness of many non regenerative (can I say That? Shouldn’t was past thinking) cells. Which we know now the are all regenerative in tissue form but the missing elements are reasons for it.
Here are a few links,
-- If God promises something, then faith must fight a long and bitter fight
For a person with chronic diabetes, life can be a gruelling battle to keep blood sugar levels close to normal. Scientific discoveries may prove vital.
Please help fund the mission of “The Cure” and for all those that currently have Diabetes or even those that may get it!
I am currently involved with Human trials for “the Cure” with Denise Faustman in Boston Mass.
Denise Faustman, is a U.S. physician and medical researcher. An associate Professor of Medicine at Harvard University, her work specializes in Diabetes mellitus type 1 (formerly called juvenile diabetes). She has worked at Massachusetts General Hospital in Boston since 1985.
On Mon. ??? waiting date, time, andfinances, for my next trip and again I am still seeking anyone who wishes to;
– come along to give blood
– Help to cover some costs
– or even advise on doing this in a less costly fashion too!
Currently travel is taking a Big chunk of my monies [AND I also need someone to go down with me!]
Look at it this way Help to find the best possible cure!!
If you feel you can assist in any way kindly leave a comment on the bottom of this post or email me directly. Thank you soooooo much!
See more about the development and research……
Faustman’s research is based on the observation that autoreactive T cells, that is, T cells programmed to attack the body’s own cells and tissues, are more sensitive to the effects of TNF-alpha (TNF-α), a cytokine that influences the immune system. TNF-α is a strong promoter of inflammation, and several treatments have been developed to block the effects of TNF-α in chronic and autoimmune diseases, including adalimumab, infliximab, and entanercept. However, side effects of these drugs include flare-ups of autoimmune symptoms.
Under some conditions, TNF-α causes T cells to undergo apoptosis, or programmed cell death. Autoimmune T cells are more sensitive to TNF-α and undergo apoptosis more readily than normal T cells when exposed to TNF-α. Faustman’s hypothesis, somewhat contrary to conventional thinking, is that blocking TNF-α actually promotes the survival of undersirable autoreactive T cells, and that autoimmune diseases should be treated by stimulating TNF-α to trigger apoptosis in self-destructive autoimmune T cells. 
Former Chrysler chairman Lee Iacocca, whose wife died of type-1 diabetes complications and who has declared a desire to see the disease cured in his lifetime, is a patron of her work. After Faustman was denied funding by the JDRF, The Iacocca Foundation provided an $11.5 million dollar grant which both supported Faustman’s work, and is being used for a clinical trial to be conducted by Harvard researcher David Nathan. This trial will not use spleen cells but only bacillus Calmette-Guerin (BCG), a weakened strain of bacteria that is used in the prevention of tuberculosis and in the treatment of bladder tumors and bladder cancer. BCG induces TNF-α. In previous human trials, it has not been shown to have a therapeutic effect in type 1 diabetics. Faustman hypothesizes that the correct dosing of BCG for diabetics has not been utilized in previous trials. As part of her research, she is seeking to define a dose that might have a therapeutic effect in the clinical trial to be led by Dr. Nathan.
Faustman’s research has been profiled in the New York Times on November 9, 2004 and March 24, 2006, and in the Wall Street Journal on March 24, 2006.
Type 1 Autoimmune Diabetes is caused by rogue T cells that attack healthy tissue. In the case of Type 1 Autoimmune Diabetes, the healthy tissue under attack are the beta cells that regulate and produce insulin. Faustman’s protocol of Freund’s adjuvant, along with the spleen cells, was effective in curing even mice with end-stage diabetes. In her human trial, scheduled for early 2008, she plans to use BCG to kill the rogue T-cells that maintain the diseased state of autoimmunity. CFA and BCG affect rogue T-cells in a peculiar way, they induce cell apoptosis, a kind of cell suicide. Normal T-cells remain unaffected. The research is promising because it is hoped that once the bad T-cells are gone, regeneration of the beta cells will ensue. However, a debate continues over the source of the islet cell regeneration.
That was the beginning but now it is even easier!!!
- Gina Kolata. “A Controversial Therapy for Diabetes Is Verified“, The New York Times, March 24, 2006. Retrieved on 2007-08-17.
- Gina Kolata. “I Beg To Differ: A Diabetes Researcher Forges Her Own Path to a Cure“, The New York Times, November 9, 2004. Retrieved on 2007-08-17.
-  Massachussetts General Hospital Diabetes Update Page
-  Wall Street Journal article, “After Initial Rejection, Scientists Back Work on Diabetes
-  Faustmanlab.org – home page regarding this research with updates and new information A small PDF best read with,
-  “Putting Up With Self” from Scientific American
- Diabetes Health article on Dr. Faustman
- Effect of BCG in Humans and Mice
- Bacillus Calmette-Guerin (BCG) Vaccine
Researchers say they may be on to a promising way to cure Type 1 diabetes in mice: stop the immune system before it kills off all the insulin-producing cells in the pancreas.
Either way, the result of the studies opens up a new route for diabetes therapy, Chong said, showing that “a diabetic mouse, even as an adult, has an ability to make new insulin-producing cells.
Your asking why I am doing this?? cuz Insulin injections for each time I eat are no longer allowing control!! Plus I take an additional two injections to help [so they say] maintain control!! BAH!
Thousands of Diabetics Report Adverse Effects from GE Insulin
Remember how safe and well tested GE products are? Well try these:
1.Real Video: Watch Fox TV investigation into claimed deaths from GE
IT IS TOO BAD THIS IN A REALPLAYER ONLY FILE> REALPLAYER = BADWARE but this may help you so much better,
Real Alternative will allow you to play RealMedia files without having to install RealPlayer. All RealMedia formats
2. More material at:
Why should we believe anyone from the genetic engineering industry? It’s no
different to the tobacco industry.
This is to say nothing of the regulatory authorities who are implicated in
this: see Canadian Class Action below.
‘It was a decision which said to me, ‘You are going to be using this
insulin – you are going to be involved in the fight of your life.’ And
that’s what’s happened’. Colleen Fuller, Candian GE insulin litigant (see
NATURAL LAW PARTY WESSEX
So now you may know more that an average diabetic, I am asking for someone who could provide Blood and Travel with me to Boston. *or* assistance with the travel costs to get there.
The cheapest way and almost easiest is with JetBlue Airlines out of Buffalo.
The Bus system I took once and it is way to time consuming and the New York stop is unbearable!
Driving is almost the same cost to get there If you wish to not sleep:)
The costs of travel is just over $200 if you spend one day 04 – 18:00 or three days on an inefficient bus system!
It is very hard to believe that so many would partake in such a selfish way to which funds can assist may in such a much larger grand scale of things!!
Newly found may not be new but is to me after looking our own canadians are involved too!
U of A terminates diabetes researcher
Investigation uncovers ‘financial irregularities’
Jodie Sinnema, The Edmonton Journal
Published: Friday, November 03, 2006
EDMONTON – The University of Alberta has terminated the employment of one of the chief researchers and doctors who headed up the internationally heralded diabetes project known as the Edmonton Protocol. Dr. Jonathan Lakey, who worked with friend and world-class surgeon Dr. James Shapiro, was terminated Thursday as a professor of surgery and university researcher.
An internal investigation discovered “financial irregularities related to his work with a third party,” University Provost Carl Amrhein said, reading from a statement.
“I am writing to inform you that Dr. Jonathan Lakey has been terminated by the University of Alberta effective immediately,” Amrhein wrote in a letter sent to about 15 staff members at Lakey’s university labs.
“Dr. Lakey has made full restitution in relationship to the financial irregularities and has decided to pursue a counselling program aimed at addressing the circumstances that gave rise to the financial issues.”
Amrhein said confidentiality rules prevent him from revealing how much money was involved, where it came from or why Lakey made the choices he did.
But he said the diabetes research projects will carry on with business as usual.
“There has been no suggestion whatsoever that research was affected, that research funds were involved or that any patient care was compromised,” Amrhein said.
Lakey was one of the principal forces behind the development of an islet-cell transplantation procedure to treat patients with severe Type 1 diabetes. In 2000, the Edmonton Protocol made headlines around the world as the first medical treatment that enabled diabetics to get off insulin.
Since then, subsequent research has found the treatment wears off over time, but is still useful with some strains of the disease.
Lakey worked closely with Dr. James Shapiro, a transplant surgeon of international repute and Lakey’s friend.
Lakey harvested the islet cells from cadavers while Shapiro did the surgeries.
In December 2005, a Journal story reported that Shapiro, Lakey and their team had more than $45 million in research grants.
At that time, Lakey and Shapiro supervised 40 staff members, many of them researchers.
While Lakey’s research position is now ended, he remains on paid leave with Capital Health.
The health authority is conducting its own investigation to determine if Lakey should also be terminated from his jobs as technical director of the Comprehensive Tissue Centre — which processes corneas, skin, bones and heart valves for transplant — and as director of the Clinical Islet Isolation Laboratory at the University of Alberta hospital.
Steve Buick, spokesman for Capital Health, said the investigation should wrap up next week and a personnel decision should be made soon.
“There will be no impact on patient services,” Buick said. Since early September, when Lakey began his paid leave, Dr. David Ross has been heading the tissue centre and Shapiro has been in charge of the islet lab.
Amrhein said the university has yet to determine who will take over Lakey’s roles on campus. Dr. Tom Marrie, the dean of medicine, will be working with Lakey’s graduate students to determine who will supervise them, Amrhein said.
Investigation uncovers ‘financial irregularities’
Jodie Sinnema, The Edmonton Journal
Published: Friday, November 03, 2006
“I have complete and total confidence in the dean and the principal (scientists) involved in the diabetes research and our colleagues at Capital Health,” he said.
“The primary concern for me is for Dr. Lakey as an individual and I think it is encouraging he has decided to pursue a counselling program.”
David Johnson, president of the Association of Academic Staff at the U of A, said he believes Lakey will stay in Edmonton to receive counselling. Johnson wouldn’t offer details on how Lakey is faring.
Calls to Lakey’s office and home went unanswered Thursday. His legal adviser also could not be reached for comment.
Johnson said his association is satisfied the university followed all the guidelines during the investigation process. He said Lakey hasn’t spoken about launching a wrongful dismissal case or about searching for another job.
The New York Times reported an internal audit at the Juvenile Diabetes Research Foundation (JDRF) discovered two men had squandered hundreds of thousands of dollars from the non-profit organization.
The two men responsible, Jonathan Stenger, national director, and Jason Brown, national manager, were dismissed late last year. Here are a few choice words for these men, in light of their insulting embezzlement. Families, friends and loved ones raised these funds to research and cure Type 1 diabetes. Shame on you! Or am I missing the Robinhood moral of this murky story? Please let these men know how you feel about their cavalier misuse of funds. Do they not know what life with diabetes is like?
There’s no excuse. In fact, I cannot stretch my imagination far enough for their irreverent and smug use of fund raising dollars. Mr. Stenger and Mr. Brown had submitted counterfeit receipts into the computer system of JDRF to protect their illicit sweepstakes – for whatever in the world they were doing.
Thankfully a JDRF internal audit discovered their inappropriate indulgence – unfortunately, the discovery came five years after it all began.
Mr. Stenger and Mr. Brown have a lot of explaining to do. Then again, no amount of explaining (or funding) has cured Type 1 diabetes. Will this be any different?
- New York Times article, Nonprofit Diabetes Group Is Subject of Investigation
- Amy Tenderich’s response to the New York Times article, Scandal at JDRF!
People must have righteous principals in the first, and then they will not fail to perform virtuous actions. Collen fuller please reply................